UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549 ~~____________________~~

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

~~THE~~ SECURITIES EXCHANGE ACT OF 1934 ~~Date of Report (Date of earliest event reported): February 1, 2018 Blake Insomnia Therapeutics, Inc. (Exact name of registrant as specified in its charter)~~

Nevada	000-55022	46-0780380
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Date of Report (Date of earliest event reported): May 7th, 2019

244, 5th Avenue, Suite A-154 New York, N.Y.	10001
(Address of principal executive offices)	(Zip Code)

BLAKE INSOMNIA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

Registrant’s telephone number, including area code: (646) 453-4912

Nevada		000-55022		46-0780380
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

~~___________________________________________________~~244 ~~(Former~~5th ~~name~~Avenue orSuite ~~former address, if changed since last report)~~A-154

~~Check~~New ~~the~~York, ~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~NY 10001

~~[ ] Written communications pursuant to Rule 425 under the Securities Act~~ (~~17CFR~~Address ~~230.425)~~of [Principal ]Executive ~~Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12~~Offices) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Indicate~~Registrant’s bytelephone ~~check~~number, ~~mark~~including ~~whether~~area ~~the~~code: ~~registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b~~+1-~~2 of the Securities Exchange Act of 1934 (§240.12b~~646-~~2 of this chapter).~~453-4912

~~Emerging~~Not ~~growth company [X]~~Applicable

If(Former anName ~~emerging~~or ~~growth~~Former ~~company~~Address, ~~indicate by check mark~~ if ~~the~~Changed ~~registrant has~~Since ~~elected~~Last ~~not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a~~Report) ~~of the Exchange Act. [X]~~

1Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

~~SECTION~~¨ 1Written –communications ~~Registrant’s~~pursuant ~~Business~~to ~~and~~Rule ~~Operations~~425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

~~Item~~The 1following discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions.01 ~~Entry~~Actual ~~into~~results and the timing of events could differ materially from those anticipated in these forward-looking statements as a ~~Material~~result ~~Definitive~~of ~~Agreement~~a number of factors, including those set forth under the Cautionary Notice Regarding Forward-Looking Statements in the Company’s recent public filings on Form 10-K and 10-Q. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “on going,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

OnChange February 1, 2018, we entered into a consulting agreement with Birger Jan Olsen. Under the consulting agreement, Mr. Olsen is to provide the following services: (1) continue managing clinical trials; (2) assist us with SEC filings; (3) assist in other duties. In consideration, we agreed to compensate Mr. Olsen with a 5% royalty for a period of 5Business ~~years for any revenue generated by us from sales of Zleepax and any new product or services derived from Zleepax. Mr. Olsen agreed to a non-compete for 2 years.~~Focus

The ~~foregoing~~Board ~~description~~ of Directors (the ~~terms~~“Board”) of Blake Insomnia Therapeutics, Inc. (the ~~consulting~~“Company”), ~~agreement does~~has ~~not~~determined ~~purport~~it to be ~~complete~~in the best interests of the Company and isits ~~subject~~shareholders to ~~and~~change ~~qualified~~the inCompany’s ~~its~~business ~~entirety~~focus byfrom ~~reference~~within tothe medical sector. As disclosed in the ~~agreement~~Company’s public reports, athe ~~copy~~Company has been focusing on improving nighttime and daytime quality of ~~which is~~life ~~filed~~for aspeople ~~Exhibits~~with 10insomnia.1 Due to ~~this~~the ~~report~~difficulties the Company has encountered with raising sufficient capital to implement the Company’s business strategy, the Board has considered various alternatives, and determined that it is in the ~~terms~~best interests of ~~which~~the ~~are~~Company ~~incorporated~~and ~~herein~~its byshareholders ~~reference~~to transition to a new market and business focus.

~~Section~~The 5Company plans to focus on establishing a foothold on the fast-growing ~~Corporate~~consumer ~~Governance~~hemp and ~~Management~~cannabidiol (CBD) market. With the passage of the 2018 Farm Bill, which formally legalized hemp crop and its extracts, primarily CBD, the Board believes that the consumer market in the US is poised for exponential growth, with projections that the CBD market is expected to reach an estimated value of $22 billion by 2022.

~~Item~~The 5Company is looking to capitalize and leverage the public markets to acquire market share through consolidation and business acquisitions.02 ~~Departure~~The ofCompany ~~Directors~~will orseek ~~Certain~~to ~~Officers;~~create ~~Election~~a ofplatform ~~Directors;~~that ~~Appointment~~will ofcombine ~~Certain~~equity ~~Officers;~~and ~~Compensatory~~capital ~~Arrangements~~to facilitate acquisitions of ~~Certain~~premium ~~Officers~~branded products.

OnThe ~~February~~Board 1,also ~~2018,~~believes ~~Birger~~that ~~Jan~~it ~~Olsen~~is ~~resigned~~in ~~from~~the ~~all~~best ~~officer positions~~interests ~~and~~of asthe aCompany ~~member~~to ofchange the ~~Board~~name of ~~Directors.~~the ~~There~~Company ~~was~~to noreflect ~~known~~the ~~disagreement~~new ~~with~~business Mrfocus. The ~~Olsen~~Company onhas ~~any~~begun ~~matter~~the ~~relating~~process of amending its articles of incorporation to ~~our operations~~change the name of the Company, ~~policies~~which orrequires ~~practices~~approval of the Board and the Shareholders. The Company will provide additional information about the name change, as well as the development of the new business strategies and their implementation, in the coming weeks.

~~Also on February 1, 2018, our Board of Directors appointed Daniel Cattlin as our President, Chief Executive Officer, Secretary, and Chief Financial Officer, Treasurer and Director.~~2

From June 2012 to October 2013, Mr. Cattlin worked for Cycad Enterprises as Operations Manager where he created budget schedules for tournaments, coordinated all logistics for teams, arranged and liaised with media and broadcasters, and aided with the negotiations of potential sponsors. From October 2013 to February 2014, Mr. Cattlin worked for News Corp UK as Online Sub-Editor where he developed and implemented new processes for online access, created and edited articles for online users, oversaw all online articles to ensure configuration with website and app services. From March 2014 to present, Mr. Cattlin works for Cyberfort Software, Inc. as CEO where he structures, negotiates and secures equity financing, oversees development for company IP, and develops, executes and monitors strategies for company’s assets and investments.SIGNATURES

~~There~~Pursuant ~~are~~to nothe ~~family~~requirements ~~relationships~~of ~~between~~the ~~Mr.~~Securities ~~Cattlin~~Exchange ~~and~~Act ~~any~~ of ~~our~~ ~~directors~~1934, orthe ~~executive~~registrant ~~officers~~has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Mr. Cattlin has not had any material direct or indirect interest in any of our transactions or proposed transactions over the last two years.

	Blake Insomnia Therapeutics, Inc.

Date: May 7, 2019	By:	/s/ Daniel Cattlin
	Name:	Daniel Cattlin
	Title:	President

~~SECTION 9 – Financial Statements and Exhibits~~3

Item 9.01 Financial Statements and Exhibits

99.1 Consulting Agreement, dated February 1, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Blake Insomnia Therapeutics, Inc.

/s/ Daniel Cattlin Daniel Cattlin Chief Executive Officer Date: March 9, 2018

Filing Compare · BIOHEMP INTERNATIONAL, INC.